Published • loading... • Updated
Larimar Targets FDA Filing for Friedreich’s Ataxia Drug
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Larimar Targets FDA Filing for Friedreich’s Ataxia Drug
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) plans to begin a rolling FDA biologics license application submission next month for its experimental Friedreich’s ataxia treatment nomlabofusp as the company advances toward potential accelerated approval. Larimar said it intends to submit the nonclinical and clinical portions of the application in June, pending additional FDA feedback, with final chemistry, manufacturing, and controls…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
